13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Nov. 27 after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer In vitro , cell culture and mouse studies identified a CDK9 inhibitor that could help treat colorectal and other cancers. Screening of a natural product library followed by chemical synthesis and...
15:29 , Nov 8, 2018 |  BC Innovations  |  Translation in Brief

Solid plans for CDK9

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include...
17:52 , Oct 26, 2018 |  BC Week In Review  |  Company News

Ultragenyx exercises option to Regenxbio gene therapy

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will exercise its option under a 2015 deal to acquire exclusive rights from RegenxBio Inc. (NASDAQ:RGNX) to develop and commercialize a gene therapy to treat cyclin...
16:57 , Oct 26, 2018 |  BC Week In Review  |  Company News

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...
17:38 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse models suggest clearing senescent cells could help treat tau-mediated neurodegenerative diseases. In a mouse model of tauopathy expressing mutant human tau in neurons, systemic expression of a fusion human transgene based on...
16:30 , Sep 21, 2018 |  BC Week In Review  |  Financial News

G1 prices $180M follow-on

G1 Therapeutics Inc. (NASDAQ:GTHX) raised $180 million in a follow-on that priced after hours on Sept. 18. G1 sold 3 million shares at $60 in an offering underwritten by J. P. Morgan, Cowen, Needham, Wedbush,...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...